Benign Prostatic Hyperplasia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Benign Prostatic Hyperplasia stocks.

Benign Prostatic Hyperplasia Stocks Recent News

Date Stock Title
May 14 BSX Here's How Much a $1000 Investment in Boston Scientific Made 10 Years Ago Would Be Worth Today
May 14 VERU Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
May 14 LLY Is Eli Lilly's Latest Deal a Gamechanger?
May 14 LLY 3 Magnificent Stocks That Are Passive Income Machines
May 14 BSX The Zacks Analyst Blog Highlights Boston Scientific, Arista Networks, Palo Alto Networks, American Electric Power and Cboe Global Markets
May 13 LLY Wegovy weight loss sustained for four years in trial, Novo Nordisk says
May 13 LLY Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients
May 13 PRCT PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
May 13 BSX Top Analyst Reports for Boston Scientific, Arista Networks & Palo Alto Networks
May 13 BSX Orthofix Medical's (OFIX) Telescopic Nail Gets FDA Clearance
May 11 LLY 1 No-Brainer Growth Stock to Buy and Hold
May 11 LLY Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
May 10 LLY Lilly could partner with Cipla to market GLP-1 drugs in India - report
May 10 BSX Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition
May 10 LLY Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
May 10 BSX AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
May 10 BSX PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up
May 10 LLY One in eight U.S. adults admits to GLP-1 usage as public awareness climbs
May 10 LLY Dividend Roundup: Eli Lilly, American Express, Microsoft, Delta Air Lines, and more
May 10 LLY How A Top Fund Beats The Market By Owning Future Leaders
Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.The cause is unclear. Risk factors include a family history, obesity, type 2 diabetes, not enough exercise, and erectile dysfunction. Medications like pseudoephedrine, anticholinergics, and calcium channel blockers may worsen symptoms. The underlying mechanism involves the prostate pressing on the urethra thereby making it difficult to pass urine out of the bladder. Diagnosis is typically based on symptoms and examination after ruling out other possible causes.Treatment options including lifestyle changes, medications, a number of procedures, and surgery. In those with mild symptoms weight loss, exercise, and decreasing caffeine intake is recommended. In those with more significant symptoms medications may include alpha blockers such as terazosin or 5α-reductase inhibitors such as finasteride. Surgical removal of part of the prostate may be carried out in those who do not improve with other measures. Alternative medicine, such as saw palmetto, does not appear to help.About 105 million people are affected globally. BPH typically begins after the age of 40. Half of males age 50 and over are affected. After the age of 80 about 90% of males are affected. Although prostate specific antigen levels may be elevated in males with BPH, the condition does not increase the risk of prostate cancer.

Browse All Tags